Phase 3 Biomarker Data Shows Valiltramiprosate Reduces Plasma p-Tau217 in APOE4/4 Carriers

Newly presented biomarker findings from the phase 3 APOLLOE4 trial (NCT04770220) suggest that valiltramiprosate (Alzheon), an investigational oral small-molecule inhibitor of amyloid oligomer formation, may engage its intended target in patients with mild cognitive impairment (MCI) because of Alzheimer disease (AD) who carry 2 copies of the APOE4 allele.¹

In the prespecified analysis, presented at the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15, in London, United Kingdom, participants with MCI treated with the agent showed a net 53% reduction in plasma phosphorylated tau 217 (p-tau217) relative to placebo over 78 weeks. Presented by lead author John Hey, PhD, chief scientific officer at Alzheon, these biomarker changes correlated with previously reported cognitive, functional, and imaging benefits.

For clinicians, this finding may matter because it adds mechanistic support to a trial that otherwise had a mixed primary readout. In the overall APOLLOE4 population, prior results showed that valiltramiprosate did not meet its primary end point of slowing decline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).^2,3 These new biomarker data are confined to the MCI stratum, where clinical benefit was previously observed, and appeared less consistent in patients with mild dementia.

Trial Design and Findings

APOLLOE4 randomized 325 APOE4/4 homozygotes with early AD, stratified into MCI (Mini-Mental State Examination [MMSE], 27-30; n = 125) and mild dementia (MMSE, 22-26; n = 200), to oral valiltramiprosate 265 mg twice daily or placebo for 78 weeks. Plasma p-tau217 and the p-tau217/Aβ42 ratio were measured every 6 months using the FDA-cleared Lumipulse G assay. Baseline testing confirmed amyloid pathology in roughly 94% of the overall cohort and 91% of the MCI group.

READ MORE: FDA Aligns With Cognition Therapeutics on Phase 3 Trial Design for Zervimesine in DLB-Associated Psychosis

In MCI participants, plasma p-tau217 declined progressively on active treatment starting around 26 weeks, whereas placebo-treated patients showed continued increases; the resulting between-group difference correlated with ADAS-Cog13, Clinical Dementia Rating - Sum of Boxes (CDR-SB), and hippocampal volume outcomes at week 78. In the mild-dementia stratum, reductions versus placebo were smaller and not statistically significant.

Clinical Context

APOE4/4 homozygotes make up an estimated 15% of patients with AD and face accelerated amyloid accumulation along with a disproportionately high risk of amyloid-related imaging abnormalities (ARIA) on approved antiamyloid monoclonal antibodies such as lecanemab (Leqembi; Eisai) and donanemab (Kisulna; Eli Lilly), complicating treatment decisions in this subgroup.⁴ An oral, nonantibody option without a signal for ARIA-E would address a genuine gap in the treatment landscape, though valiltramiprosate remains investigational and is not approved yet anywhere.

Drug Background

Valiltramiprosate is a valine-conjugated prodrug of tramiprosate, a glycosaminoglycan-mimetic compound that binds soluble Aβ42 monomers to block oligomerization. Tramiprosate itself was previously studied as Alzhemed in phase 3 trials that failed to meet primary end points in the mid-2000s, though post hoc analyses suggested a possible dose-dependent benefit in APOE4 carriers, prompting the compound's later marketing as an unregulated supplement (Vivimind) before its reformulation as ALZ-801.⁵

Click here for more coverage of AAIC 2026.

REFERENCES
1. Hey JA, Abushakra S, Liang E, et al. Valiltramiprosate On Plasma p-Tau217, p-Tau217/Ab42, vMRI And Clinical Correlations In Phase 3 APOE4/4 Early AD Subjects. Presented at: 2026 Alzheimer’s Association International Conference; July 12-15; London, United Kingdom.
2. Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene. News release. Alzheon. April 10, 2025. Accessed July 10, 2026. https://alzheon.com/topline-results-from-pivotal-apolloe4-phase-3-trial-of-oral-valiltramiprosate-alz-801-in-patients-with-early-alzheimers-disease-carrying-two-copies-of-apoe4-gene/
3. Abushakra S, Power A, Watson D, et al. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025;85(11):1455-1472. doi:10.1007/s40265-025-02250-5
4. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
5. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13(6):550-557. doi:10.1007/s12603-009-0106-x